Connect Biopharma Holdings Limited, a global clinical-stage biopharmaceutical company specializing in therapies for chronic inflammatory diseases, unveiled additional findings from its pivotal trial for atopic dermatitis during the 2023 World Congress of Dermatology. The data highlighted the effectiveness and safety of rademikibart (formerly known as CBP-201) in treating moderate-to-severe atopic dermatitis in China. The presentation covered primary and secondary endpoints, improvements observed by investigators, and enhancements reported by patients.
At the 25th World Congress of Dermatology, Connect Biopharma showcased four posters containing comprehensive and novel data on the attainment of primary and secondary endpoints, improvements noted by investigators, and enhancements reported by patients after a 16-week treatment period with rademikibart. These posters demonstrated that rademikibart successfully met all primary and secondary endpoints in a randomized pivotal trial for moderate-to-severe atopic dermatitis in China. Furthermore, they exhibited significant improvements in Eczema Area and Severity Index scores, indicating the drug's efficacy and safety.
The first poster presentation